Business Wire

Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD

Share

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. (China) (“Hasten”), a company funded by Feidong County of Hefei City, China and established by Ray Capital Management Limited (“Ray Capital”)1 Takeda will receive $322 million USD, subject to customary legal and regulatory closing conditions.

The portfolio to be divested to Hasten includes cardiovascular and metabolism products sold in mainland China. The portfolio generated FY2019 net sales of approximately $109.5 million USD, driven by strong sales of cardiovascular products such as Ebrantil®. While the products included in the sale continue to play important roles in meeting patient needs in the country, they are outside of Takeda's chosen business areas – Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience – that are core to its global long-term growth strategy.

“China is an important market for Takeda in our efforts to accelerate the availability of our highly innovative medicines to patients living with complex and rare diseases,” said Ricardo Marek, President, Growth & Emerging Markets Business Unit, Takeda. “This sale will further sharpen Takeda’s focus and resources in fast tracking innovation in China, and the Emerging Markets. At the same time, we are confident that under Ray Capital, Hasten will be well-positioned to provide continued patient access to these trusted products in China.”

“This announcement marks continued progress on our commitment to simplify our global portfolio and remain focused on investing in our growth drivers, and research and development pipeline,” said Costa Saroukos, Chief Financial Officer, Takeda. “We remain committed to expansion in China with more than 15 planned approvals over the next five years. By continuing to execute and deliver on Takeda’s financial commitments, including paying down debt and focusing on our highly innovative portfolio, we can sustain our long-term growth and continue to deliver life-transforming treatments for patients worldwide.”

Takeda intends to use the proceeds from its divestitures to continue to reduce its debt and accelerate deleveraging toward its target of 2x net debt/adjusted EBITDA within FY2021 – FY2023.

Takeda has sustained momentum in its divestiture strategy in 2020 and exceeded its $10 billion non-core asset divestiture target, announcing 10 deals since January 2019 to date for a total aggregate value of up to ~$11.3 billion, including agreements to divest:

  • Takeda Consumer Healthcare Company Limited to Oscar A-Co KK, a company controlled by funds managed by The Blackstone Group Inc. and its affiliates for a total value of approximately JPY 242.0 billion ($2.3 billion USD).
  • Other non-core portfolio assets within the Growth & Emerging Markets Business Unit, totaling up to approximately ~$2 billion with four separate buyers.2
  • Select OTC and non-core assets in Europe to Orifarm for up to approximately $670 million.
  • Non-core assets in Europe and Canada to Cheplapharm for approximately $562 million.
  • The TachoSil Fibrin Sealant Patch to Corza Health, Inc. for €350 million.

Transactions still pending are expected to close by March 31, 2021, subject to customary legal and regulatory closing conditions.

Transaction Details

Takeda has entered into an agreement to sell a portfolio of five select non-core prescription pharmaceutical assets sold in mainland China to Hasten for $322 million USD.

Under the terms of the agreement, Hasten will acquire the rights, title and interest to the products in the portfolio exclusive to China. Employees who are dedicated to the commercial support of these products today will be transferred to Hasten. Takeda and Hasten have also entered into a manufacturing and supply agreement under which Takeda will continue to manufacture the portfolio of divested products and supply them to Hasten.

The agreement is expected to close by June 30, 2021, subject to the satisfaction of customary closing conditions, receipt of required regulatory clearances and, where applicable, satisfaction of local works council requirements. Until then, Takeda remains the owner of these products.

Takeda is being advised by BofA Securities as its financial advisor and White & Case is its legal advisor in this transaction.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.

Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit https://www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company

Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

1 Ray Capital is a biopharmaceutical investment company established by the Government of Hefei Municipality.

2Includes agreement with Hypera S.A. for the sale of select non-core products in Latin America which remains subject to close; and, completed sales of non-core assets in the Russia-CIS region to STADA, the Near East, Middle East and Africa region to Acino, and Asia Pacific to Celltrion Inc.

Contact information

Investor Relations
Christopher O’Reilly
takeda.ir.contact@takeda.com
+81 (0) 3-3278-2306

Media Contacts:
Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095

Media outside Japan
Justine Grosvenor
justine.grosvenor@takeda.com
+1 872-226-6701

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AGCO Announces Organizational Update25.1.2021 22:31:00 CETPress release

AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and solutions, today announced intended changes and recent additions to its senior leadership team to further increase customer focus and strengthen investment in precision agriculture and digital solutions to maximize stakeholder value. Robert Crain will be the Senior Vice President leading the newly formed Customer Experience team charged with delivering the best end-to-end customer experience in the industry. Seth Crawford has joined the senior team in the new role of Senior Vice President, Precision Ag and Digital to reinforce AGCO’s commitment to delivering industry-leading, smart farming solutions. Following a successful, 22-year tenure at Deere & Company, Mr. Crawford joined AGCO in 2019 to lead its Fuse Connected Services and Technology division. Additionally, other members of the senior team will assume worldwide responsibility for AGCO’s core brands to maximize brand value

Mytheresa Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares25.1.2021 22:15:00 CETPress release

MYT Netherlands Parent B.V. (“Mytheresa” or the “Company”), the parent company of Mytheresa Group GmbH, today announced the closing of its initial public offering of 17,994,117 American Depositary Shares (“ADSs”), representing 17,994,117 ordinary shares, including the full exercise by the underwriters of their option to purchase 2,347,058 additional ADSs, representing 2,347,058 ordinary shares, at a public offering price of $26.00 per ADS. The Company sold 14,233,823 ADSs in the offering and its sole shareholder sold 3,760,294 ADSs in the offering, including 586,764 ADSs sold by the Company and 1,760,294 ADSs sold by the sole shareholder pursuant to the exercise in full of the underwriters’ option to purchase additional ADSs. Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC acted as lead joint bookrunning managers and representatives of the underwriters for the offering. Credit Suisse Securities (USA) LLC and UBS Securities LLC acted as joint bookrunning managers for the offerin

UAEREP Launches Fourth Cycle and Starts Receiving Project Proposals25.1.2021 17:11:00 CETPress release

The UAE Research Program for Rain Enhancement Science (UAEREP) announced the launch of its fourth cycle at the fifth International Rain Enhancement Forum (IREF), convened virtually under the patronage of His Highness Sheikh Mansour bin Zayed Al Nahyan, UAE Deputy Prime Minister and Minister of Presidential Affairs. Submissions are open to innovative project proposals from across the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005618/en/ UAEREP’s 4th Cycle Now Open! (Graphic: AETOSWire) The program offers a grant of up to US$1.5 million, distributed over three years with a maximum annual amount of $550,000 for each winning research proposal in the rain enhancement field. Over its past three cycles, the program has provided grants to nine ground-breaking projects that covered different fields related to rain enhancement and weather modification research. Interested academic institutions, research centers and ot

PPG Donates Coatings, Sealants to Help Restore Douglas C-54 Skymaster Aircraft25.1.2021 17:02:00 CETPress release

PPG (NYSE:PPG) today announced that it recently supplied coatings and sealants to help restore a 74-year-old, four-engine transport aircraft – the Douglas C-54 Skymaster, serial number 56498. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005599/en/ PPG today announced that it recently supplied coatings and sealants to help restore a 74-year-old, four-engine transport aircraft – the Douglas C-54 Skymaster, serial number 56498. (Photo: Business Wire) Manufactured in 1945, the aircraft was used by the U.S. Army Air Force as a workhorse to transport medical supplies, troops and military equipment during World War II, the Korean War and the Vietnam War. It left military service in 1973 and was flown as a sprayer from 1975 to 1985. After its first restoration was completed in 2002, the aircraft was flown to England to be featured in a film about the Berlin Airlift. The film was cancelled, and the C-54 Skymaster sat exposed

E-Fuel Corporation: “Rejected Energy” the Real Culprit Behind Climate Change and How to Stop It25.1.2021 17:00:00 CETPress release

The E-Fuel Corporation, a Texas-based technology firm, has come up with a revolutionary way to repurpose the largest energy source on the planet ‘rejected energy,’ which experts have identified as a leading cause of climate change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005050/en/ The E-Fuel Corporation has come up with a revolutionary way to repurpose the largest energy source on the planet; rejected energy. (Photo: Business Wire) According to research conducted by the Lawrence Livermore National Laboratory and the US Department of Energy, rejected energy accounted for an astonishing 67.5 percent of the total energy consumed within the US in 2019. To put this in simple terms, if you placed three gallons of fuel into your vehicle, only one gallon provides mechanical energy to rotate the wheels and the remaining two gallons are rejected through the radiator, tailpipe, and engine friction heat into the atmosphere

Mawi DNA’s Extractionless Sample Collection Technology Enables BioTech Africa Launch of Affordable COVID-19 Mass Testing Platform25.1.2021 15:00:00 CETPress release

Mawi DNA Technologies’ iSWAB-Microbiome-EL sample collection technology enables BioTech Africa to implement and launch a new ultra-high throughput COVID-19 testing program. This breakthrough, in conjunction with the ProbeSure™ COVID-19 One Step RT-PCR Kit from 3CR Bioscience, is designed to scale up to a capacity of 200,000 tests per day. “We are extremely proud and humbled to be part of South Africa’s fight against COVID-19 through BioTech Africa’s mass testing efforts,” said Dr. Bassam El-Fahmawi, President and CTO, Mawi DNA Technologies. In addition, Dr. Jenny Leslie, COO of BioTech Africa, worked closely with Scilutions Labware and Hook Diagnostics to identify the best products and supplier partners who could provide reagents to streamline the testing workflow, but also scale to the projected numbers with minimal supply chain disruption. “For the sample collection step, Mawi DNA Technologies’ iSWAB-Microbiome-EL (‘Extractionless’) product was chosen for its multiple benefits. This

AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-225.1.2021 14:13:00 CETPress release

Today, AchilleS Vaccines, a biotech company based in Siena (Italy), announced the successful industrial development of a novel monoclonal antibody (mAb) to treat COVID-19. The treatment, patented by Prof Rino Rappuoli’s MAD Lab and developed by AchilleS, could greatly improve access to COVID-19 treatment and has several advantages compared to conventional mAbs: it can be administered intramuscularly, avoiding the risks of hospitalization. Additionally, this mAb is highly potent and the low dosage treatment offers significant health and cost benefits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005376/en/ AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-2 (Photo: AchilleS Vaccines) The AchilleS antibody project ‘mAbCo19’ will now be further tested in the clinic, possibly leading to an emergency market authorization this summer. AchilleS is developing this new therapeutic in c